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Uremic toxins are known to affect the regenerative
properties of tissue-resident and circulating stem cells
and thus appear to be a limiting factor for autologous
stem cell-based approaches for treating chronic
kidney disease. The recent article by van Koppen and
colleagues in Stem Cell Research & Therapy provides
evidence that an ex vivo short-term pre-treatment
with statins reverts the dysfunction of bone marrow
stem cells isolated from rats with renal impairment.
Indeed, statin pre-treated cells improved renal function
in a model of established chronic kidney disease. Our
commentary discusses the potential of this approach in
the context of autologous cell therapy and the
available knowledge on the mechanisms involved in
uremia-induced stem cell dysfunction.Statin pre-treated CKD BMCs, but not untreated cells, im-
proved renal function in terms of glomerular filtration rateChronic kidney disease (CKD) is a life-threatening con-
dition characterized by glomerulosclerosis and tubular
atrophy, leading to progressive and irreversible loss of
renal function. Several of the compounds retained dur-
ing progressive renal failure, so-called uremic toxins,
display oxidative and pro-inflammatory action with sys-
temic detrimental effects. In this context, increasing
data in the literature point out that uremic toxins also
affect the functional properties of tissue-resident and
circulating stem cells, including bone marrow-derived
hematopoietic and stromal cells [1–4].
For several reasons, the damaging effect of uremic
toxics on stem cells therefore appears to be a major
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creativecommons.org/publicdomain/zero/1.0/approaches for treating CKD. First, the autologous
source of stem cells appears to be of reduced therapeutic
interest for patients with CKD, as these cells partially
lack regenerative potential. In addition, the uremic toxic
milieu may affect stem cells isolated from healthy sub-
jects once injected in patients with CKD. The recent art-
icle by van Koppen and colleagues [1] in Stem Cell
Research & Therapy reports an interesting ex vivo ap-
proach aimed at overcoming the regenerative impairment
of bone marrow stem cells (BMCs) isolated from CKD rats
(CKD BMCs). The authors provide evidence that an
ex vivo short-term pre-treatment (2 hours) with the
cholesterol-lowering drug pravastatin is able to revert the
loss of regenerative properties of CKD BMCs [1]. In fact,
pre-treated cells administered in a single dose to rats with
an established CKD showed a therapeutic efficacy in vivo
that was similar to that of BMCs isolated from healthy rats.
and effective renal plasma flow increase, reduced urea, and
limited the generation of glomerular and interstitial scler-
osis [1].
BMCs have been proposed as an attractive approach for
cell therapy because of their regenerative efficacy, and the
number of clinical trials is consistently increasing. Never-
theless, the possibility of obtaining an autologous source
of a large number of cells in the absence of cell expansion
in culture makes BMCs a safe and clinically feasible strat-
egy. The experimental approach proposed by van Koppen
and colleagues in CKD rats further supports the clinical
interest in BMCs, which were effective in a therapeutic ad-
ministration protocol for rats already presenting renal
function impairment (6 weeks after the 5/6 nephrectomy)
[1]. Moreover, the ex vivo manipulation of stem cells with
statins followed an easily applicable procedure. Additional
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of interest, as it could provide clinically relevant informa-
tion to assess stem cell potency before injection and to
identify strategies to manipulate stem cells ex vivo.
At present, the analysis of molecular alterations in-
duced by uremia was reported only for endothelial pro-
genitor cells (EPCs) [2] and mesenchymal stromal cells
(MSCs) [3, 5, 6]. The detrimental effect of toxins on the
EPC compartment has been observed even in cases of
mild CKD [2]. Uremic toxins, used in concentrations
found in patients with CKD, exerted in vitro an anti-
proliferative effect on EPCs, affecting the mitogen-
activated protein kinase pathway, but did not induce
EPC apoptosis [7]. Moreover, they inhibited MSC meta-
bolic activity and proliferation and, more relevantly, al-
tered the secretory activity of MSCs in terms of
decreased level of vascular endothelial growth factor and
transforming growth factor-beta 1 [3]. It could be specu-
lated that uremia induces epigenetic changes in the
BMC genome, inducing a premature senescence and an
altered secretion profile, as described for MSCs [8, 9].
By analogy with MSCs, paracrine mechanisms possibly
account for the therapeutic activity of BMCs in CKD pre-
clinical models, as BMCs release cytokines and growth
factors that stimulate the endogenous repair and induce
the angiogenic process [10]. Indeed, no integration of
BMCs into renal parenchyma was observed [10]. However,
the analysis of the secretome in CKD and healthy BMCs
as well as in statin-treated cells did not significantly differ
in terms of released factors, as only the inflammatory che-
mochine CXCL-5 was decreased after treatment [1]. It is
conceivable that other secreted factors, including exo-
somes and extracellular vesicles, could be involved and
modulated by statins.
Statins have been described to ameliorate stem cell
functions, such as proliferation, migration, adhesion, and
angiogenic ability, on cells isolated from a healthy sub-
ject. In addition, they were effective in the prevention of
senescence [11]. By analogy, in CKD-derived BMCs, sta-
tins appeared to increase migratory properties in vitro
and to restore therapeutic potential in vivo [1]. Besides
uremia, systemic diseases such as diabetes and inflam-
matory conditions as well as advanced age may affect
BMC functionality [3, 4]. Therefore, the search for
pharmacological strategies to bypass the patient-related
dysfunction of stem cells and, in particular, of BMCs ap-
pears to be of great interest for autologous therapy. It
would be relevant to evaluate whether the effect of sta-
tins is restricted to uremia-induced alterations in BMCs
or could be extended to other stem cell types and detri-
mental conditions. Another proposed approach is based
on hypoxia preconditioning of BMCs, which rescued the
dysfunction of BMCs from aged mice and enhanced
their adhesion, survival, and angiogenic potency [12].In conclusion, strategies of ex vivo manipulation of
stem cells are required to restore the regenerating effi-
cacy lost under systemic inflammatory conditions, in-
cluding uremia, to allow their use in an autologous
manner. Statins appear to be an easily applicable and
functional strategy for the autologous use of BMCs in
CKD in pre-clinical models. The validation of this ap-
proach in different stem cell types as well as in human
cells would be of great clinical interest.
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